There's been a major selloff in IRIDEX Corporation (NASDAQ:IRIX) shares in the week since it released its annual...
MOUNTAIN VIEW, Calif., Nov. 05, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Healthcare Conference in New.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / IRIDEX Corp. (NASDAQ:IRIX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 5:00 PM Eastern ...
MOUNTAIN VIEW, Calif., May 11, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 28, 2020. Commenting on the.
Q3 2019 IRIDEX Corp Earnings Call
IRIDEX Corporation's (NASDAQ:IRIX): IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic...
IRIDEX Corporation (IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Romeo Dizon has retired from his position as Vice President of Finance, effective March 27, 2020. Mr. Dizon has agreed to continue to serve as needed as a consultant to facilitate a smooth transition and to provide additional support through the end the Company’s first quarter 2020 reporting cycle. IRIDEX’s Board of Directors has appointed James Mackaness to serve as interim Chief Financial Officer while it searches for a successor to Mr. Dizon.
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., Feb. 28, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year of.
Iridex (IRIX) delivered earnings and revenue surprises of 31.25% and 0.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
MOUNTAIN VIEW, Calif., March 12, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 28, 2019. Fourth Quarter.
Iridex (IRIX) delivered earnings and revenue surprises of 29.41% and -5.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Q4 2019 IRIDEX Corp Earnings Call
MOUNTAIN VIEW, Calif., April 28, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2020 after the.
MOUNTAIN VIEW, Calif., Nov. 07, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 28, 2019. Third Quarter.
IRIDEX Corporation (IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today the introduction of the second generation of the MicroPulse P3® Device, which has been redesigned to deliver greater stability, visualization, coupling, and fit. More than 120,000 patients have been treated in over 60 countries with the original version of the MicroPulse P3 Device.
Market forces rained on the parade of IRIDEX Corporation (NASDAQ:IRIX) shareholders today, when the analysts...
IRIDEX Corporation (IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Doris Engibous to its board of directors effective April 20, 2020. The Company will also nominate Ms. Engibous for re-election to the board at its 2020 Annual Meeting of Stockholders. “I am delighted to welcome Doris to our board of directors,” said Robert Gunst, chairman of the board of IRIDEX.
Anyone researching IRIDEX Corporation (NASDAQ:IRIX) might want to consider the historical volatility of the share...
IRIDEX Corporation (IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 28, 2019. Total revenue for the fourth quarter of 2019 expected to be $11.6 - $11.8 million, compared to $11.5 million in the fourth quarter of 2018. “We are pleased with our solid results for the fourth quarter and look to build on those in 2020,” said David I. Bruce, President and CEO of IRIDEX.